Nasdaq · Healthcare
Progyny, Inc. (PGNY)
As-reported financials and recent SEC filings for Progyny, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.29B
Net income
$58.5M
Net margin
4.5%
Diluted EPS
$0.65
ROE
11.3%
P/E (TTM)
37.0×
Market cap
$2.23B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.09B | $786.9M | $500.6M |
| Gross profit | $304.5M | $253.4M | $238.8M | $167.3M | $112.1M |
| Operating income | $85.3M | $67.5M | $62.2M | $23.3M | $32.3M |
| Net income | $58.5M | $54.3M | $62.0M | $30.4M | $65.8M |
| Diluted EPS | $0.65 | $0.57 | $0.62 | $0.30 | $0.66 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →SCHEDULE 13G/A2026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →1442026-06-04
View on EDGAR →1442026-06-04
View on EDGAR →1442026-06-03
View on EDGAR →Go deeper on PGNY
Search Progyny, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.